U.S. FDA approves AstraZeneca’s lung cancer drugs

3:30 am Friday, November 11th, 2022

(Reuters) – Drugmaker AstraZeneca said on Friday its lung cancer drugs Imfinzi and Imjudo have been approved by the U.S. Food and Drug Administration (FDA) when used along with chemotherapy for treatment of adults with stage IV non-small cell lung cancer.

(Reporting by Amna Karimi in Bengaluru; Editing by Sherry Jacob-Phillips)

6 mins ago

ECB has room to cut rates but should take its time, policymakers say

24 mins ago

Argentina markets keep wary eye on Milei reform bill hold-ups

40 mins ago

Brazil inflation expectations to improve over time, says central bank chief